Last reviewed · How we verify
NCT04975867
Adjunct Targeted Temperature Management in Acute Severe Carbon Monoxide Poisoning
NA trial testing Targeted therapeutic hypothermia in Carbon Monoxide Poisoning in 46 participants. Participants enrolled and being followed up; not accepting new ones.
31 December 2025
Quick facts
| Lead sponsor | Wonju Severance Christian Hospital |
|---|---|
| Phase | NA |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 46 |
| Start date | 25 October 2021 |
| Primary completion | 31 December 2025 |
| Estimated completion | 31 December 2025 |
| Sites | 2 locations across South Korea |
Drugs / interventions tested
- Targeted therapeutic hypothermia
- Targeted therapeutic normothermia
Conditions studied
- Carbon Monoxide Poisoning — all drugs for Carbon Monoxide Poisoning →
- Neurologic Sequelae — all drugs for Neurologic Sequelae →
- Hypothermia — all drugs for Hypothermia →
Sponsor
Wonju Severance Christian Hospital
Who can join
19 and older, any sex, with Carbon Monoxide Poisoning or Neurologic Sequelae. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This randomized trial will investigate important neurocognitive clinical outcomes of patients with acute severe carbon monoxide poisoning (ASCOP) randomized to receive either therapeutic hypothermia or normothermia combined with hyperbaric oxygen therapy (HBO).
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04975867
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Carbon Monoxide Poisoning
Currently open trials in the same condition.
- NCT06811675 — The Efficacy of Dexamethasone in Combination With N-acetylcysteine in Preventing Neurocognitive Sequelae Due to Carbon M · Phase 4 · recruiting
- NCT06549621 — Cardiotoxicity of Carbon Monoxide in Patients Treated With Hyperbaric Oxygen Therapy · recruiting
Other Wonju Severance Christian Hospital trials
Trials by the same sponsor.
- NCT07012499 — QOL and Mental Health Using APD With Remote Monitoring System · NA · enrolling by invitation
- NCT07146178 — Long-term Follow-up of Bio-signals and Quality of Recovery Following Implementation of ERAS · NA · not yet recruiting
- NCT06675396 — Pharmacogenomics of Mood Disorder in Chronic Kidney Disease Patients · not yet recruiting
- NCT06540430 — Digital Based Home Care Service for Ostomy Patients · NA · not yet recruiting
- NCT07017088 — Efficacy of Leuconostoc Mesenteroides · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04975867 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Wonju Severance Christian Hospital
- Last refreshed: 15 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04975867.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing